PMID: 3294977Jun 1, 1987

A dose-response study of the bronchodilator action of azelastine in asthma

The Journal of Allergy and Clinical Immunology
J P KempJ L Perhach

Abstract

Azelastine is an orally effective inhibitor of mediator activity in allergic reactions and has also been demonstrated to have bronchodilator activity. In this randomized, double-blind, placebo-controlled, multicenter study, 150 patients, aged 12 to 60 years, with moderate to severe asthma, received a single oral dose of 2, 4, 8, 12, or 16 mg of azelastine or placebo. Theophylline was stopped 24 hours and other bronchodilators at least 8 hours before the study day. Patients were evaluated for 8 hours after dose by spirometry and were monitored for adverse effects. All doses of azelastine produced bronchodilation with 4 mg greater than 2 mg greater than placebo; higher doses did not increase magnitude or duration of effect. We conclude that azelastine produces significant bronchodilation of long duration. The optimal dose appears to be 4 mg for adolescent and adult patients with asthma.

References

Dec 1, 1989·The Journal of Allergy and Clinical Immunology·F E Simons
Jan 4, 2001·Progress in Lipid Research·B A Goins, W T Phillips
Dec 3, 1999·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·S L Spector
Apr 9, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·C FukushimaS Asai
Jan 1, 1997·Allergy·A Malick, J A Grant
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P H Howarth
Aug 1, 1990·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S J Rimmer, M K Church
Aug 1, 1990·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P H Howarth
Feb 1, 1992·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M H ShinR M Naclerio
Mar 1, 1992·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·G BalzanoG Seccia
Sep 1, 1988·The Journal of Allergy and Clinical Immunology·E O MeltzerG R Hemsworth
May 1, 1989·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P Rafferty, S T Holgate
Nov 1, 1989·The Journal of Pediatrics·S R Wynn
Dec 1, 1988·The Journal of Allergy and Clinical Immunology·P RaffertyS T Holgate
May 1, 1988·Chest·H MagnussenR Aurich
Apr 1, 1989·The Journal of Allergy and Clinical Immunology·T B Casale
Aug 1, 1989·The Journal of Allergy and Clinical Immunology·P Rafferty, S T Holgate
Jan 1, 1995·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·P ChervinskyJ J Freitag

Related Concepts

Broncholytic Effect
Adverse Effects
Bronchodilator Agents
Loxin
Asthma
Mediator of activation protein
Theophylline
Theophylline Assay
Bronchodilation
Monospan

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergies & Environmental Factors

Environmental factors are strongly associated with the prevalence of allergies and are an increasing health concern worldwide. Discover the latest research on Allergies and Environmental Factors here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.